Men with a single negative prostate biopsy have a 20-year cumulative rate of prostate cancer diagnosis of 23.7%.
New tool promises to help patients decide whether radical prostatectomy or radiation therapy is their best treatment option.
The authors of a recent editorial offer an explanation for why radium-223 used in combination with abiraterone and prednisone did not lower the risk of symptomatic skeletal events and death among men with metastatic castration-resistant prostate cancer.
This survey assessed the opinions of oncologists, urologists, and oncology nurses on the use of shared decision-making in older men with metastatic castration-resistant prostate cancer.
Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.
Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.
Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.
Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate CancerFebruary 15, 2019
At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.
By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.
After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.
The Decipher genomic classifier predicted metastases and prostate cancer-specific mortality following radical prostatectomy with greater precision in African-American men.
The study is the first to show that treatment with abiraterone acetate/enzalutamide is associated with better survival in African American patients with mCRPC compared with Caucasians.
Median metastasis-free survival was longer with darolutamide than with placebo: 40.4 vs 18.4 months.
In a "real world" study, biopsy and surgical grade groups 2, 3, 4, and 5 each were associated with incrementally higher risks for adverse pathologic features and biochemical recurrence.
A high percentage of men with prostate cancer have 1 or more potentially pathogenic germline variants, but would not be eligible for mutation testing under current NCCN guidelines.
From 2010 to 2015, active surveillance/watchful waiting increased from 14.5% to 42.1%, according to a new study.
In a small study, men on androgen deprivation therapy for prostate cancer lost weight and experienced improved hemoglobin A1C and lipid profiles.
Men with advanced disease report health-related quality of life similar to that of those with localized disease.
Compared with patients on maintenance dialysis, men with prostate cancer and women with breast cancer have better unadjusted 5-year survival probabilities.
Weight loss in the first year after starting androgen deprivation therapy in men who have undergone radical surgery for prostate cancer ups the risk of metastatic disease and death from prostate cancer.
Study finds 18 vs 6 months of androgen suppression and radiotherapy for locally advanced prostate cancer is associated with a 30% decreased risk of death from the disease.
In a study of men with nonmetastatic high-risk prostate cancer who have rising PSA after primary therapy, investigators found no significant difference in PSA progression-free survival.
Androgen deprivation therapy recipients had a significantly lower risk for autoimmune diseases overall and for Graves' disease, uveitis, and psoriasis.
Finasteride tied to lower risk for death from prostate cancer, but lower risk not statistically significant
Men with unfavorable-risk prostate cancer who had a detectable PSA nadir and a time to PSA nadir less than 12 months had a 5-fold increased risk of dying from their disease.
Five-year rates of biopsy progression-free, treatment-free, and cancer-specific survival are similar for men younger than 60 and those aged 60 and older when placed on active surveillance.
Negative findings on a confirmatory fusion biopsy are associated with a lower risk of Grade Group progression.
The MSI-H/dMMR phenotype in men with advanced PCa is associated with greater likelihood of a durable response to PD-1/PD-L1 inhibitors.
Standardized mortality ratio highest for cancers of lung, head and neck, testes, bladder, Hodgkin lymphoma.
Reduction in trial discussions, trial offers, trial participation seen with one or more comorbidities.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)